Related Experiment Videos
Short-course chemotherapy for tuberculosis in children
Insights
Short-course chemotherapy using rifampin and isoniazid is a safe and effective treatment for childhood tuberculosis. This regimen demonstrated excellent results with minimal toxicity in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Pulmonary Medicine
- Pharmacology
Background:
- Tuberculosis (TB) treatment in children requires effective and safe regimens.
- Short-course chemotherapy was introduced for adult pulmonary TB in 1976.
- Pediatric TB treatment protocols needed evaluation for efficacy and safety.
Purpose of the Study:
- To evaluate the efficacy and safety of a short-course, twice-weekly chemotherapy regimen for treating tuberculosis in children.
- To assess the treatment outcomes and drug toxicity in pediatric patients with pulmonary and extrapulmonary TB.
Main Methods:
- A cohort of 50 children (4 months to 15 years) with tuberculosis received daily rifampin and isoniazid for one month, followed by twice-weekly doses for eight months.
- Diagnosis was based on purified protein derivative (PPD) skin testing, chest radiography, and clinical findings.
- Treatment outcomes, including symptom resolution and radiographic clearing, were monitored.
Main Results:
- Excellent treatment results were observed, with symptoms clearing in 1-2 months.
- Pulmonary infiltrates resolved in most cases by 10 months; hilar adenopathy took longer.
- Drug toxicity was minimal, with only one instance of vomiting attributed to rifampin.
Conclusions:
- Short-course chemotherapy with rifampin and isoniazid is a safe, effective, and well-tolerated treatment for childhood tuberculosis.
- The regimen's simplicity and short duration facilitate adherence and administration, especially in socially disadvantaged families.
- This approach offers a practical solution for managing pediatric TB, ensuring better patient cooperation and outcomes.
Abstract:
Short-course, largely twice-weekly chemotherapy for tuberculosis was introduced in the United States for treatment of adults with pulmonary disease by the Arkansas State Department of Health in 1976. Since 1977, 50 children with tuberculosis have been treated with rifampin, 10 to 20 mg/kg, and isoniazid, 10 to 20 mg/kg daily for one month followed by 10 to 20 mg/kg of rifampin and 20 to 40 mg/kg of isoniazid twice a week for another 8 months. Ages ranged from 4 months to 15 years with a median age of 3 years. A presumptive diagnosis of tuberculosis was made on the basis of 10 mm or more of induration to 5 TU of purified protein derivative and a chest film or other findings compatible with tuberculosis. Three children had extrapulmonary disease (two had cervical adenitis, one had tuberculosis arthritis). Of the 47 children with pulmonary disease, 32 were asymptomatic. The results were excellent. Symptoms cleared in 1 to 2 months. Most pulmonary infiltrates had cleared by 10 months, but hilar adenopathy rarely cleared in less than 2 years. Drug toxicity occurred in only one patient (vomiting of rifampin). This treatment appears to be safe, effective, inexpensive, short and simple enough to ensure cooperation or to allow personnel to administer drugs directly to children from socially disorganized families.